2. Jinyu Pharmaceutical (603882): The annual report of 2020 shows that Jinyu Pharmaceutical achieved a net profit of 15 1 billion yuan, up by 275.24% year-on-year. The company is a leader in the domestic third-party medical examination industry. Relying on its own professional advantages such as virus detection ability and logistics network, it actively undertakes the heavy responsibility of virus nucleic acid detection in key areas including Thunder God Mountain hospital, Wuhan and Hubei, and provides detection support for epidemic prevention and control with the socialized force of third-party physical examination.
3. Mike Audi (300341): The 2020 annual report shows that Mike Audi achieved a net profit of 654.38+3.9 billion yuan, a year-on-year increase of -6.24%. In April 2000, it was revealed that Xiamen Maiaodi Medical Laboratory Co., Ltd., a subsidiary of the Department of Medicine, undertook part of COVID-19 nucleic acid detection business in Xiamen. Xiamen Maiaodi Laboratory, a subsidiary of the company, has the qualification of nucleic acid detection and is one of the designated institutions for virus nucleic acid detection in Xiamen.
4. Henderson Land Trust (002492): According to the 2020 annual report, Henderson Land Trust achieved a net profit of 1.0 1 billion yuan, a year-on-year increase of 92.04%. In February, 2000, it was revealed that novel coronavirus test kit had been developed in the project invested by Big Health Investment Fund, and an emergency visit application was submitted to National Medical Products Administration (NMPA).
5. Dean Diagnosis (300244): The company's net profit in 2020 is 803 million yuan. In February, 2000, the company developed novel coronavirus (20 19-nCoV) nucleic acid detection kit (PCR- fluorescence probe method), and completed the detection process suitable for clinical use. In May, 2000, the nucleic acid detection capacity of Hangzhou headquarters laboratory reached 65,438+10,000 cases.